What is the official website of Eurofins Genomics ?

The official website of Eurofins Genomics is https://eurofinsgenomics.eu.

What is Eurofins Genomics's cybersecurity risk score?

Eurofins Genomics has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Eurofins Genomics experienced?

According to Rankiteo, Eurofins Genomics currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Eurofins Genomics been affected by any supply chain cyber incidents ?

According to Rankiteo, Eurofins Genomics has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Eurofins Genomics have SOC 2 Type 1 certification ?

According to Rankiteo, Eurofins Genomics is not certified under SOC 2 Type 1.

Does Eurofins Genomics have SOC 2 Type 2 certification ?

According to Rankiteo, Eurofins Genomics does not hold a SOC 2 Type 2 certification.

Does Eurofins Genomics comply with GDPR ?

According to Rankiteo, Eurofins Genomics is not listed as GDPR compliant.

Does Eurofins Genomics have PCI DSS certification ?

According to Rankiteo, Eurofins Genomics does not currently maintain PCI DSS compliance.

Does Eurofins Genomics comply with HIPAA ?

According to Rankiteo, Eurofins Genomics is not compliant with HIPAA regulations.

Does Eurofins Genomics have ISO 27001 certification ?

According to Rankiteo,Eurofins Genomics is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Eurofins Genomics operate in ?

Eurofins Genomics operates primarily in the Biotechnology Research industry.

How many employees does Eurofins Genomics have ?

Eurofins Genomics employs approximately 326 people worldwide.

Does Eurofins Genomics own any subsidiaries ?

Eurofins Genomics presently has no subsidiaries across any sectors.

How many LinkedIn followers does Eurofins Genomics have ?

Eurofins Genomics's official LinkedIn profile has approximately 19,566 followers.

Does Eurofins Genomics have a Crunchbase profile ?

No, Eurofins Genomics does not have a profile on Crunchbase.

Does Eurofins Genomics have a LinkedIn profile ?

Yes, Eurofins Genomics maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/eurofinsgenomics.

How many cybersecurity incidents has Eurofins Genomics experienced ?

As of August 9, 2026, Rankiteo reports that Eurofins Genomics has not experienced any cybersecurity incidents.

How many peer or competitor companies does Eurofins Genomics have ?

Eurofins Genomics has an estimated 4,739 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Eurofins Genomics

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Eurofins Genomics Vendor Cyber Rating & Cyber Score

eurofinsgenomics.eu

Add Your Compliance Badge

Eurofins Genomics was founded in 1990 and is part of the Eurofins Scientific Group, a Life Science Company with laboratories in 61 countries and 61,000 employees. We are an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis. Our services are tailored for pharma, diagnostics, agriculture, food, biotechnology and research applications worldwide. Imprint: https://www.eurofinsgenomics.eu/imprint/ Privacy Note: https://www.eurofinsgenomics.eu/privacy/

Eurofins Genomics A.I CyberSecurity Scoring

Scoring History

Eurofins Genomics

Eurofins Genomics CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Eurofins Genomics Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Eurofins Genomics

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Eurofins Genomics in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Eurofins Genomics in 2026.

Incident Types Eurofins Genomics vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Eurofins Genomics in 2026.

Incident History - Eurofins Genomics (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Eurofins Genomics Subsidiaries

Eurofins Genomics

Biotechnology Research

Website: https://eurofinsgenomics.eu

Company Size: 326

EurofinsBiotechnology Research

Eurofins Clinical Trial SolutionsBiotechnology Research

Eurofins Lancaster LaboratoriesBiotechnology Research

Eurofins PSS Insourcing SolutionsBiotechnology Research

Eurofins BioPharma Product Testing ItalyPharmaceutical Manufacturing

Eurofins AdvinusResearch Services

Eurofins Discovery Services IndiaResearch

Eurofins Advinus Agrosciences IndiaResearch Services

Eurofins BioPharma Product Testing India Pharmaceutical Manufacturing

Eurofins IT Delivery CenterIT Services and IT Consulting

Eurofins Agroscience ServicesResearch

Eurofins Agroscience Biological SolutionsResearch

Eurofins Agroscience Seed ServicesResearch Services

Eurofins Agroscience Regulatory ConsultancyResearch Services

Eurofins Agroscience Environmental SafetyResearch

Eurofins Agroscience Biological AssessmentResearch Services

Eurofins Agroscience Consumer/Human SafetyResearch Services

Eurofins Agroscience Product ChemistryResearch Services

Eurofins do Brasil Análises de Alimentos e AmbientaisResearch Services

Eurofins Environment Testing (USA)Environmental Services

Eurofins Biopharma Product Testing (France)Pharmaceutical Manufacturing

Eurofins Food AssuranceProfessional Services

Eurofins Environment Testing FranceBiotechnology

Eurofins | Solutions DurablesServices de conseil en environnement

Eurofins Analyses Alimentaires FranceBiotechnology Research

Eurofins BiomnisMedical and Diagnostic Laboratories

Eurofins Central LaboratoryBiotechnology Research

Eurofins US Food, Feed, & Supplement TestingBiotechnology Research

Eurofins Food, Feed & Water BeneluxBiotechnology Research

Eurofins DiscoverXBiotechnology Research

Eurofins Clinical DiagnosticsBiotechnology

Eurofins CDMOPharmaceutical Manufacturing

Eurofins CDMO AlphoraPharmaceutical Manufacturing

Eurofins ViracorMedical and Diagnostic Laboratories

ExPeCT™ anti-CD19 (FMC63) CAR TMedical and Diagnostic Laboratories

Eurofins Viracor CMV TestingBiotechnology Research

TTViWATCH™ - Torque Teno Virus qPCRMedical and Diagnostic Laboratories

Eurofins Danmark - LaboratoriumBiotechnology Research

Eurofins Steins LaboratoriumBiotechnology Research

Eurofins Product Testing Denmark A/SSecurity and Investigations

Eurofins Agro & HortiResearch Services

Eurofins DiscoveryBiotechnology

Eurofins ChileFood and Beverage Services

Eurofins Genomics AmericasBiotechnology

Eurofins CanadaBiotechnology Research

Eurofins Environment BeneluxEnvironmental Services

DiatherixBiotechnology Research

Loading…

Eurofins Genomics Similar Companies

Genentech

gene.com

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

Amgen

amgen.com

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Syneos Health

cb syneoshealth.com

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Loading…

NEWS

Eurofins Genomics CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-71983

SUMMARY

MSI Radix AXE6600 router firmware version v781521 contains a command injection vulnerability in the wps.cgi interface that allows remote attackers to execute arbitrary commands by injecting malicious input through the pin2g, pin5g, or pin6g parameters. Attackers can exploit these unsanitized parameters to execute arbitrary commands on the affected device and obtain root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71502

SUMMARY

CTI-Transmute contains a stored cross-site scripting vulnerability caused by insufficient neutralization of Vue template expression delimiters in server-rendered user-controlled data. An unauthenticated attacker can create a public conversion whose name or description contains a malicious Vue expression using the application's configured [[ ... ]] delimiters. User profile names may provide an additional injection vector. Although Jinja HTML escaping is applied, the resulting value is subsequently included in a DOM region compiled by Vue. Vue interprets the attacker-controlled value as a template expression rather than ordinary text. By accessing the JavaScript Function constructor from within the expression, an attacker can execute arbitrary JavaScript in the security context of the CTI-Transmute origin. The application's nonce-based Content Security Policy does not prevent exploitation because the Vue runtime compiler requires the unsafe-eval policy exception. The malicious payload is stored by the application and executed whenever another user opens an affected page, such as the public conversion detail page. The victim may be a normal user or an administrator. Successful exploitation could allow the attacker to: * Access data available to the victim through the application. * Extract API keys, tokens, or other sensitive information exposed to the page. * Perform authenticated actions using the victim's session. * Modify conversions or other application data. * Escalate the impact by targeting an administrator. A demonstrated payload can use [].constructor.constructor(...) to obtain the JavaScript Function constructor and execute arbitrary code. The regression tests also show that a short first-stage payload could retrieve an uncapped conversion description and evaluate a larger second-stage payload. The patch addresses the vulnerability by registering a global Jinja finalize hook that inserts a zero-width Unicode word joiner inside every Vue delimiter found in server-rendered values. This prevents Vue from recognizing the values as template expressions while preserving their visible representation.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: )

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-71958

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the quicksetup.cgi interface. A remote attacker can write overly long strings to the test4, ssid2, and username fields and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71957

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the app.cgi interface. A remote attacker can write an overly long string to the netAcc.addlist[].name field and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71956

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a command injection vulnerability in the app.cgi interface. A remote attacker can inject arbitrary malicious commands into the netDig.ping.dst field, resulting in command execution with root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…